Fujian Haixi Pharmaceuticals Co., Ltd. Class H

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H carries a market capitalization of 10.70B, placing it among publicly traded companies globally. Its enterprise value stands at 9.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H has 78.71M shares outstanding.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H trades at a trailing price-to-earnings ratio of 47.98. The price-to-sales ratio is 14.59, and the price-to-book ratio stands at 6.04.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H trades at an EV/EBITDA multiple of 42.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 44.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Fujian Haixi Pharmaceuticals Co., Ltd. Class H trades at an EV/FCF ratio of 69.93, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 9.35B versus a market cap of 10.70B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H maintains a current ratio of 6.31, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.91, indicating elevated leverage, while an interest coverage ratio of 34.32 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. The company generates approximately 3.24M in revenue per employee across its workforce of 200.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H recorded 23.42M in income tax expense. That works out to an effective tax rate of 10.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 220.44M, leaving 197.01M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Fujian Haixi Pharmaceuticals Co., Ltd. Class H's stock has gained approximately 39.14% over the past 52 weeks. The 50-day moving average sits at 182.97, while the 200-day moving average is 178.72.

Over the twelve months ended December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H generated 648.10M in revenue and converted that into 197.01M in net income, yielding earnings per share of 2.83. EBITDA reached 219.10M, while operating income came in at 219.71M.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H holds 1.48B in cash and equivalents against 122.58M in total debt, resulting in a net debt position of -602.41M. Total book value stands at 1.77B, with working capital of 1.35B providing operational flexibility.

Fujian Haixi Pharmaceuticals Co., Ltd. Class H produced 177.93M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -49.99M in capital expenditures, free cash flow totaled 127.94M - equivalent to 1.84 per share.

Over the twelve months ended December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H posted a gross margin of 83.38, reflecting its pricing power and cost economics. The operating margin of 33.90 and net profit margin of 30.40 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 1.35, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -9.68, meaning Fujian Haixi Pharmaceuticals Co., Ltd. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. Class H has an Altman Z-Score of 24.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.